Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Covalon Technologies Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific action is assigned to VANHORN, ABIGAIL LOUISE, who serves as the busiest examiner for the company with 1 pending case. The portfolio's current prosecution is limited to 1 distinct examiner and 1 distinct art unit. This indicates a high degree of technical and procedural focus, as the 1 pending office action is not distributed across multiple departments.
For the practitioner, this suggests that the prosecution success for the Biotechnology & Pharmaceuticals filings currently rests on the 1 distinct examiner's review. The concentration in 1 distinct art unit implies that the claims are tightly focused within a specific technical domain. Because the 1 pending office action is the only active matter, the examiner's individual interpretation of the prior art will be the decisive factor. Practitioners should prepare for a prosecution environment where the 1 distinct examiner's previous decisions in the Biotechnology & Pharmaceuticals area will heavily influence the outcome of the 1 pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17213783 | ANTIMICROBIAL COMPOSITION | VANHORN, ABIGAIL LOUISE | 18d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17213783 | ANTIMICROBIAL COMPOSITION | VANHORN, ABIGAIL LOUISE | 18d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17213783 | ANTIMICROBIAL COMPOSITION | VANHORN, ABIGAIL LOUISE | 1636 | §103§112 | Non-Final OA | 18d overdue | Pending | Mar 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCovalon Technologies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Abigail Louise Vanhorn has the most, with 1 of Covalon Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
